Babak Razavi, MD
Neurology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 18
- 4 carriers
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
18 plans · 4 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Razavi’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
18 of 18 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A115797 · Current
Licensed to practise in California · since 2011 · expires 2028-10-31 · University of Rochester School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$52,323
Medicare paid this office $52,323 for 208 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Measurement of brain wave activity with video (veeg), 12-26 hours with review and report by health care professional | 64 | $19,214 | $187 |
| Long return visit (40+ min) | 22 | $5,493 | $157 |
| Return visit (30+ min) | 30 | $4,314 | $111 |
| Long return visit (40+ min) | 12 | $2,874 | $125 |
| Measurement of brain wave activity with video (veeg), 2-12 hours with review and report by health care professional | 21 | $2,547 | $116 |
See all 10 services
| Measurement of brain wave activity with video (veeg), 12-26 hours with review and report by health care professional | 64 | $19,214 | $187 |
| Long return visit (40+ min) | 22 | $5,493 | $157 |
| Return visit (30+ min) | 30 | $4,314 | $111 |
| Long return visit (40+ min) | 12 | $2,874 | $125 |
| Measurement of brain wave activity with video (veeg), 2-12 hours with review and report by health care professional | 21 | $2,547 | $116 |
| Short return visit (20+ min) | 25 | $2,171 | $80 |
| Return visit (30+ min) | 11 | $1,403 | $83 |
| Measurement of brain wave activity (eeg), awake and asleep | 14 | $727 | $52 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 35 | $659 | $15 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 14 | $330 | $15 |
Who their Medicare patients are
208 Original Medicare patients in 2024. Average age 66 · Under 65 31% · 85 and older 9% · Women 54% · Also on Medicaid 42% · Health risk score 1.95. Above the middle of the specialty; the typical neurology clinician is at 1.61.
Conditions among them: High blood pressure 62% · Stroke 34% · Depression 28% · Dementia 27% · Coronary heart disease 26% · Diabetes 25% · Atrial fibrillation 24% · Chronic kidney disease 20% · Heart failure 19% · Cancer 19% · COPD 12%.
The office billed $442,111, Medicare allowed $68,226 and paid $52,323; for 490 services of 30 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 208 | 490 | 66 | 1.95 | $442,111 | $52,323 |
| 2023 | 211 | 413 | 65 | 1.92 | $699,725 | $45,666 |
| 2022 | 212 | 428 | 64 | 1.96 | $928,198 | $48,018 |
| 2021 | 212 | 390 | 65 | 1.71 | $928,079 | $44,841 |
| 2020 | 199 | 339 | 64 | 1.78 | $686,605 | $34,602 |
| 2019 | 234 | 458 | 65 | 1.69 | $215,471 | $68,257 |
| 2018 | 204 | 367 | 63 | 1.89 | $123,457 | $47,156 |
| 2017 | 184 | 370 | 65 | 2.14 | $149,605 | $55,046 |
| 2016 | 172 | 399 | 66 | 1.60 | $157,891 | $54,065 |
| 2015 | 62 | 99 | 64 | 2.29 | $40,734 | $14,395 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 7 services
| Measurement of brain wave activity with video (veeg), 12-26 hours with review and report by health care professional | 58 | $18,656 | $188 |
| Long return visit (40+ min) | 33 | $5,650 | $123 |
| Return visit (30+ min) | 41 | $4,714 | $77 |
| Short return visit (20+ min) | 34 | $2,395 | $56 |
| Measurement of brain wave activity with video (veeg), 2-12 hours with review and report by health care professional | 19 | $2,340 | $123 |
| Measurement of brain wave activity (eeg), 2-12 hours with health care professional review and report | 11 | $1,028 | $93 |
| Measurement of brain wave activity (eeg), awake and drowsy | 11 | $583 | $53 |
2022: 8 services
| Measurement of brain wave activity with video (veeg), 12-26 hours with review and report by health care professional | 61 | $21,818 | $191 |
| Return visit (30+ min) | 44 | $5,423 | $85 |
| Long return visit (40+ min) | 18 | $4,621 | $132 |
| Short return visit (20+ min) | 45 | $2,904 | $51 |
| Measurement of brain wave activity with video (veeg), 2-12 hours with review and report by health care professional | 18 | $2,371 | $125 |
| Measurement of brain wave activity (eeg), 2-12 hours with health care professional review and report | 13 | $1,221 | $94 |
| Measurement of brain wave activity (eeg), awake and asleep | 16 | $866 | $54 |
| Short return visit | 12 | $308 | $22 |
2021: 6 services
| Measurement of brain wave activity with video (veeg), 12-26 hours with review and report by health care professional | 65 | $23,041 | $194 |
| Return visit (30+ min) | 42 | $4,704 | $84 |
| Short return visit (20+ min) | 43 | $3,082 | $56 |
| Measurement of brain wave activity with video (veeg), 2-12 hours with review and report by health care professional | 19 | $2,513 | $126 |
| Measurement of brain wave activity (eeg), 2-12 hours with health care professional review and report | 11 | $1,125 | $94 |
| Short return visit | 11 | $351 | $27 |
2020: 6 services
| Measurement of brain wave activity with video (veeg), 12-26 hours with review and report by health care professional | 43 | $17,163 | $195 |
| Return visit (30+ min) | 45 | $3,832 | $61 |
| Measurement of brain wave activity with video (veeg), 2-12 hours with review and report by health care professional | 16 | $2,009 | $126 |
| Short return visit (20+ min) | 20 | $1,021 | $44 |
| Telephone medical discussion with physician, 11-20 minutes | 17 | $844 | $44 |
| Short return visit | 14 | $287 | $20 |
2019: 8 services
| Monitoring and localization of seizure activity over 24-hour period using 16-channel electroencephalograph (EEG) | 65 | $43,773 | $296 |
| Return visit (30+ min) | 81 | $8,515 | $65 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 12 | $3,496 | $92 |
| Long return visit (40+ min) | 21 | $2,168 | $99 |
| New patient visit (60+ min) | 12 | $1,828 | $152 |
| Measurement of brain wave activity (eeg), awake and drowsy | 21 | $1,134 | $54 |
| Measurement of brain wave activity (eeg), awake and asleep | 16 | $864 | $54 |
| Short return visit (20+ min) | 12 | $420 | $35 |
2018: 7 services
| Monitoring and localization of seizure activity over 24-hour period using 16-channel electroencephalograph (EEG) | 49 | $25,021 | $294 |
| Return visit (30+ min) | 60 | $4,850 | $59 |
| New patient visit (60+ min) | 23 | $2,953 | $128 |
| Return visit (30+ min) | 34 | $2,482 | $67 |
| New patient visit (60+ min) | 13 | $1,813 | $139 |
| Long return visit (40+ min) | 12 | $1,059 | $81 |
| Measurement of brain wave activity (eeg), awake and asleep | 15 | $797 | $53 |
2017: 5 services
| Monitoring and localization of seizure activity over 24-hour period using 16-channel electroencephalograph (EEG) | 65 | $36,943 | $293 |
| Return visit (30+ min) | 56 | $7,383 | $67 |
| New patient visit (60+ min) | 16 | $2,391 | $149 |
| Long return visit (40+ min) | 15 | $1,372 | $91 |
| Measurement of brain wave activity (eeg), awake and asleep | 13 | $690 | $53 |
2016: 4 services
| Monitoring and localization of seizure activity over 24-hour period using 16-channel electroencephalograph (EEG) | 41 | $28,606 | $292 |
| Return visit (30+ min) | 55 | $6,470 | $65 |
| New patient visit (60+ min) | 39 | $5,391 | $138 |
| Long return visit (40+ min) | 24 | $2,775 | $99 |
2015: 3 services
| New patient visit (60+ min) | 27 | $4,057 | $150 |
| Long return visit (40+ min) | 16 | $1,593 | $100 |
| Return visit (30+ min) | 14 | $1,125 | $70 |
Medicaid work
$13,208 in 2024
Medicaid paid $13,208 for 100 billed services this clinician did in 2024, up to 14 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Electroencephalogram (EEG), continuous recording, physician or other qualified health care professional review of recorded events, analysis of spike and seizure detection, each increment of greater than 12 hours, up to 26 hours of EEG recording, interpretation and report after each 24-hour period; with video (VEEG) | 88 | $12,551 |
| Return visit (30+ min) | 12 | $657 |
| 2024 | 100 | 2 | 14 | $13,208 |
| 2023 | 174 | 3 | 18 | $11,363 |
| 2022 | 126 | 3 | 21 | $12,428 |
| 2021 | 52 | 2 | 18 | $12,730 |
| 2019 | 131 | 1 | 26 | $3,989 |
| 2018 | 165 | 1 | 19 | $6,853 |
See the largest Medicaid services in earlier years
2023
| Electroencephalogram (EEG), continuous recording, physician or other qualified health care professional review of recorded events, analysis of spike and seizure detection, each increment of greater than 12 hours, up to 26 hours of EEG recording, interpretation and report after each 24-hour period; with video (VEEG) | 64 | $7,372 |
| Return visit (30+ min) | 86 | $3,423 |
| Short return visit (20+ min) | 24 | $569 |
2022
| Electroencephalogram (EEG), continuous recording, physician or other qualified health care professional review of recorded events, analysis of spike and seizure detection, each increment of greater than 12 hours, up to 26 hours of EEG recording, interpretation and report after each 24-hour period; with video (VEEG) | 82 | $11,220 |
| Return visit (30+ min) | 16 | $608 |
| Short return visit (20+ min) | 28 | $600 |
2021
| Electroencephalogram (EEG), continuous recording, physician or other qualified health care professional review of recorded events, analysis of spike and seizure detection, each increment of greater than 12 hours, up to 26 hours of EEG recording, interpretation and report after each 24-hour period; with video (VEEG) | 36 | $12,218 |
| Return visit (30+ min) | 16 | $511 |
2019
| Return visit (30+ min) | 131 | $3,989 |
2018
| Return visit (30+ min) | 165 | $6,853 |
Drugs they prescribed that Part D paid
$777,595
Pharmacies billed $777,595 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 1,214) in 2024. At or below the middle of the specialty; the typical neurology clinician is at 0%.
909 generic and 262 brand-name prescriptions · $777,595 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Fycompa | 41 | $99,287 | $2,422 |
| Xcopri | 27 | $94,096 | $3,485 |
| Nayzilam | 35 | $85,124 | $2,432 |
| Epidiolex | 27 | $82,551 | $3,057 |
| Vimpat | 35 | $80,497 | $2,300 |
See all 28 drugs
| Fycompa | 41 | $99,287 | $2,422 |
| Xcopri | 27 | $94,096 | $3,485 |
| Nayzilam | 35 | $85,124 | $2,432 |
| Epidiolex | 27 | $82,551 | $3,057 |
| Vimpat | 35 | $80,497 | $2,300 |
| Briviact | 29 | $60,603 | $2,090 |
| Onfi | 17 | $55,707 | $3,277 |
| Lacosamide | 91 | $22,049 | $242 |
| Lamotrigine Er | 47 | $13,423 | $286 |
| Levetiracetam Er | 59 | $11,793 | $200 |
| Levetiracetam | 165 | $10,078 | $61 |
| Dilantin | 30 | $7,374 | $246 |
| Clobazam | 33 | $6,840 | $207 |
| Felbamate | 13 | $5,553 | $427 |
| Pregabalin | 56 | $5,196 | $93 |
| Lamotrigine | 66 | $3,562 | $54 |
| Klonopin | 17 | $3,520 | $207 |
| Divalproex | 44 | $2,939 | $67 |
| Oxcarbazepine | 24 | $2,470 | $103 |
| Phenobarbital | 43 | $2,320 | $54 |
| Gabapentin | 57 | $2,027 | $36 |
| Divalproex Sodium Er | 25 | $1,892 | $76 |
| Zonisamide | 17 | $788 | $46 |
| Clonazepam | 50 | $273 | $5 |
| Topiramate | 18 | $269 | $15 |
| Diazepam | 19 | $233 | $12 |
| Lorazepam | 46 | $152 | $3 |
| Alprazolam | 12 | $121 | $10 |
Year by year
| 2024 | 1,214 | 124 | 0% (0) | 22% | $777,595 |
| 2023 | 979 | 116 | None | 22% | $569,355 |
| 2022 | 791 | 129 | None | 21% | $388,661 |
| 2021 | 644 | 109 | 0% (0) | 18% | $200,117 |
| 2020 | 594 | 109 | 0% (0) | None | $310,719 |
| 2019 | 700 | 103 | 0% (0) | 24% | $273,743 |
| 2018 | 510 | 82 | 0% (0) | None | $125,004 |
| 2017 | 351 | 59 | None | None | $60,666 |
| 2016 | 193 | 46 | 0% (0) | None | $15,520 |
| 2015 | 37 | 16 | 0% (0) | None | $3,984 |
| 2014 | 34 | 11 | None | None | $12,115 |
| 2013 | 201 | 47 | None | None | $53,727 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 29 drugs
| Fycompa | 47 | $86,528 | $1,841 |
| Vimpat | 27 | $58,010 | $2,149 |
| Nayzilam | 19 | $51,678 | $2,720 |
| Xcopri | 25 | $36,635 | $1,465 |
| Lamictal Xr | 11 | $35,798 | $3,254 |
| Briviact | 18 | $24,123 | $1,340 |
| Lacosamide | 62 | $23,089 | $372 |
| Lamotrigine Er | 22 | $18,641 | $847 |
| Rufinamide | 15 | $17,263 | $1,151 |
| Clobazam | 30 | $15,908 | $530 |
| Levetiracetam | 153 | $13,797 | $90 |
| Oxtellar Xr | 11 | $13,216 | $1,201 |
| Levetiracetam Er | 46 | $9,006 | $196 |
| Oxcarbazepine | 13 | $4,445 | $342 |
| Pregabalin | 59 | $4,145 | $70 |
| Dilantin | 12 | $3,601 | $300 |
| Klonopin | 22 | $3,122 | $142 |
| Lamotrigine | 51 | $2,085 | $41 |
| Divalproex | 34 | $2,083 | $61 |
| Phenobarbital | 30 | $2,057 | $69 |
| Gabapentin | 43 | $1,917 | $45 |
| Zonisamide | 16 | $1,105 | $69 |
| Topiramate | 14 | $997 | $71 |
| Diazepam | 16 | $938 | $59 |
| Clonazepam | 25 | $454 | $18 |
| Divalproex Sodium Er | 11 | $421 | $38 |
| Carbamazepine | 12 | $341 | $28 |
| Lorazepam | 42 | $126 | $3 |
| Alprazolam | 11 | $35 | $3 |
2022: 22 drugs
| Vimpat | 30 | $60,837 | $2,028 |
| Fycompa | 40 | $48,427 | $1,211 |
| Epidiolex | 11 | $30,774 | $2,798 |
| Nayzilam | 12 | $26,757 | $2,230 |
| Lacosamide | 32 | $19,048 | $595 |
| Xcopri | 13 | $18,611 | $1,432 |
| Levetiracetam Er | 43 | $16,948 | $394 |
| Lamotrigine Er | 19 | $14,340 | $755 |
| Levetiracetam | 131 | $8,184 | $62 |
| Clobazam | 16 | $7,979 | $499 |
| Pregabalin | 29 | $4,375 | $151 |
| Dilantin | 12 | $3,397 | $283 |
| Oxcarbazepine | 11 | $3,336 | $303 |
| Topiramate | 16 | $2,799 | $175 |
| Lamotrigine | 78 | $2,510 | $32 |
| Klonopin | 24 | $2,185 | $91 |
| Phenobarbital | 12 | $1,102 | $92 |
| Diazepam | 11 | $897 | $82 |
| Gabapentin | 38 | $895 | $24 |
| Divalproex | 15 | $418 | $28 |
| Clonazepam | 34 | $418 | $12 |
| Lorazepam | 44 | $186 | $4 |
2021: 15 drugs
| Vimpat | 49 | $53,008 | $1,082 |
| Fycompa | 17 | $28,306 | $1,665 |
| Lamotrigine Er | 21 | $17,351 | $826 |
| Aptiom | 12 | $15,724 | $1,310 |
| Levetiracetam | 132 | $7,711 | $58 |
| Levetiracetam Er | 19 | $5,023 | $264 |
| Clobazam | 15 | $2,274 | $152 |
| Divalproex | 19 | $2,010 | $106 |
| Lamotrigine | 43 | $1,689 | $39 |
| Phenobarbital | 21 | $1,459 | $69 |
| Gabapentin | 37 | $1,202 | $32 |
| Clonazepam | 49 | $638 | $13 |
| Carbamazepine | 16 | $425 | $27 |
| Diazepam | 12 | $321 | $27 |
| Lorazepam | 33 | $83 | $3 |
2020: 13 drugs
| Vimpat | 37 | $57,399 | $1,551 |
| Oxtellar Xr | 11 | $7,371 | $670 |
| Levetiracetam | 131 | $5,854 | $45 |
| Levetiracetam Er | 18 | $5,842 | $325 |
| Clobazam | 12 | $2,066 | $172 |
| Divalproex | 16 | $1,516 | $95 |
| Diazepam | 17 | $1,422 | $84 |
| Lamotrigine | 47 | $1,382 | $29 |
| Phenytoin Sodium Extended | 11 | $1,100 | $100 |
| Gabapentin | 39 | $725 | $19 |
| Zonisamide | 11 | $688 | $63 |
| Clonazepam | 32 | $435 | $14 |
| Lorazepam | 30 | $98 | $3 |
2019: 20 drugs
| Fycompa | 30 | $47,566 | $1,586 |
| Vimpat | 33 | $34,657 | $1,050 |
| Keppra Xr | 14 | $22,738 | $1,624 |
| Lamictal | 11 | $11,728 | $1,066 |
| Lamotrigine Er | 24 | $10,357 | $432 |
| Levetiracetam Er | 47 | $9,811 | $209 |
| Oxtellar Xr | 15 | $9,775 | $652 |
| Keppra | 11 | $5,102 | $464 |
| Clobazam | 12 | $3,995 | $333 |
| Levetiracetam | 127 | $3,433 | $27 |
| Dilantin | 18 | $2,679 | $149 |
| Lamotrigine | 45 | $1,240 | $28 |
| Phenobarbital | 18 | $1,082 | $60 |
| Zonisamide | 23 | $1,028 | $45 |
| Gabapentin | 43 | $605 | $14 |
| Divalproex | 20 | $394 | $20 |
| Clonazepam | 19 | $235 | $12 |
| Lorazepam | 29 | $141 | $5 |
| Fluoxetine | 11 | $76 | $7 |
| Diazepam | 11 | $48 | $4 |
2018: 14 drugs
| Fycompa | 20 | $21,397 | $1,070 |
| Onfi | 16 | $20,962 | $1,310 |
| Vimpat | 16 | $12,149 | $759 |
| Levetiracetam | 130 | $4,983 | $38 |
| Levetiracetam Er | 36 | $3,304 | $92 |
| Lamotrigine | 55 | $1,697 | $31 |
| Divalproex | 31 | $1,634 | $53 |
| Zonisamide | 20 | $1,365 | $68 |
| Topiramate | 14 | $1,278 | $91 |
| Oxcarbazepine | 16 | $963 | $60 |
| Carbamazepine | 12 | $630 | $53 |
| Gabapentin | 29 | $444 | $15 |
| Clonazepam | 13 | $90 | $7 |
| Lorazepam | 12 | $33 | $3 |
2017: 9 drugs
| Vimpat | 34 | $22,936 | $675 |
| Levetiracetam | 116 | $3,723 | $32 |
| Carbamazepine | 15 | $1,256 | $84 |
| Divalproex | 20 | $726 | $36 |
| Oxcarbazepine | 21 | $714 | $34 |
| Clonazepam | 14 | $612 | $44 |
| Zonisamide | 13 | $461 | $35 |
| Lamotrigine | 22 | $383 | $17 |
| Topiramate | 13 | $211 | $16 |
2016: 5 drugs
| Levetiracetam | 78 | $2,979 | $38 |
| Carbamazepine | 11 | $1,216 | $111 |
| Oxcarbazepine | 11 | $495 | $45 |
| Topiramate | 20 | $369 | $18 |
| Zonisamide | 24 | $323 | $13 |
2015: 1 drug
| Levetiracetam | 16 | $558 | $35 |
2013: 5 drugs
| Levetiracetam | 13 | $890 | $68 |
| Divalproex | 11 | $665 | $60 |
| Atorvastatin | 18 | $644 | $36 |
| Clopidogrel | 14 | $337 | $24 |
| Metoprolol | 13 | $91 | $7 |
Money from drug and device companies
$13 in 2024
| 2024 | 1 | 1 | None | $13 |
| 2020 | 1 | 1 | None | $49 |
| 2019 | 1 | 1 | None | $38 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Neurelis | Valtoco | $13 | 1 payment
|
See the published payment
| Neurelis | Education · 2024-02-26 | Valtoco | $13 |
See earlier years (2020, 2019)
2020: $49
| Eisai | Fycompa | $49 | 1 payment
|
2019: $38
| Eisai | Fycompa | $38 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| NEUROPACE, INC. · Post Approval Study · 2022 | This clinician | $35,755 |
| NEUROPACE, INC. · Post Approval Study · 2024 | This clinician | $31,264 |
| NEUROPACE, INC. · Post Approval Study · 2025 | This clinician | $28,673 |
| NEUROPACE, INC. · Investigator Initiated Retrospective Outcomes Studies · 2019 | This clinician | $13,200 |
| NEUROPACE, INC. · Post Approval Study · 2019 | This clinician | $11,664 |
| NEUROPACE, INC. · Post Approval Study · 2023 | This clinician | $10,776 |
| NEUROPACE, INC. · Post Approval Study · 2020 | This clinician | $10,224 |
| Eisai Inc. · Multicenter, Open-Label Study To Evaluate the Efficacy and Safety of Perampanel As Monotherapy Or First Adjunctive Therapy in Subjects With Partial Onset Seizures With Or Without Secondarily Generalized Seizures Or With Primary Generalized Tonic-Clonic Seizures · 2019 | Their institution | $3,622 |
| NEUROPACE, INC. · Post Approval Study · 2021 | This clinician | $2,924 |
| Eisai Inc. · Multicenter, Open-Label Study To Evaluate the Efficacy and Safety of Perampanel As Monotherapy Or First Adjunctive Therapy in Subjects With Partial Onset Seizures With Or Without Secondarily Generalized Seizures Or With Primary Generalized Tonic-Clonic Seizures · 2020 | Their institution | $1,582 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1851533855
- Licence
- CA A115797California A115797: Current · expires 2028-10-31
- Trained
- University of Rochester School of Medicine and Dentistry, 2009
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 2084E0001X (2084E0001X); Neurology (2084N0400X); Federal specialty code 2084N0600X (2084N0600X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2009-04-06
- NPI last updated
- 2023-11-13
- NPI record certified
- 2023-11-13
This is when the NPI record was last certified, not a medical board exam.